Gestational Trophoblastic Disease: Symptoms, Diagnosis & Treatment

Introduction

Gestational trophoblastic disease (GTD) is a rare group of pregnancy-related conditions characterized by abnormal cell growth within the uterus. These conditions arise from the tissue formed after conception, specifically the trophoblast cells, which normally develop into the placenta. GTD can range from benign (non-cancerous) to malignant (cancerous) forms. Early diagnosis and treatment are essential to prevent complications. GTD was first recognized as a distinct medical condition in the early 20th century, and advances in medical technology have since improved both diagnosis and treatment, leading to better patient outcomes.

This article provides a clear, patient-friendly overview of gestational trophoblastic disease, covering its risk factors, symptoms, diagnostic tests, treatment options, and steps patients can take at home to manage their symptoms.

Definition of Gestational Trophoblastic Disease

Gestational trophoblastic disease (GTD) refers to a group of pregnancy-related conditions involving abnormal cell growth in the uterus. This article will discuss risk factors, symptoms, diagnostic tests, treatment options, and home management strategies for patients with GTD.

Description of Gestational Trophoblastic Disease

Gestational trophoblastic disease (GTD) encompasses a group of rare conditions that occur when abnormal cells grow in the tissue formed after conception, specifically the trophoblast cells. These cells are responsible for developing the placenta, which nourishes the fetus during pregnancy. In GTD, these cells grow uncontrollably, forming tumors. Types of GTD include hydatidiform mole (molar pregnancy), invasive mole, choriocarcinoma, and placental-site trophoblastic tumor (PSTT).

GTD can be benign or malignant. The most common form, hydatidiform mole, is typically benign but can sometimes progress to choriocarcinoma, a cancerous condition. If untreated, malignant GTD can spread to other parts of the body, such as the lungs or brain, making early diagnosis and treatment essential.

GTD is rare, affecting about 1 in 1,000 pregnancies in the United States, though it is more common in regions like Southeast Asia and Latin America. With early detection and appropriate treatment, the prognosis for most GTD patients is excellent, with cure rates exceeding 90% for many forms of the disease.

Risk Factors for Developing Gestational Trophoblastic Disease

Lifestyle Risk Factors

While lifestyle factors are not the primary cause of gestational trophoblastic disease, certain habits and environmental influences may increase the risk. For instance, inadequate nutrition, particularly a diet low in carotene and vitamin A, has been linked to a higher incidence of GTD. Women with multiple pregnancies may also have a slightly increased risk. However, lifestyle factors alone are not typically the sole cause of GTD.

Smoking and exposure to environmental toxins may also contribute to the risk of GTD, though more research is needed to confirm these connections. Maintaining a healthy lifestyle, including a balanced diet and avoiding harmful substances, can help reduce the risk of pregnancy-related complications, including GTD.

Medical Risk Factors

Several medical conditions and factors can increase the likelihood of developing gestational trophoblastic disease. One of the most significant risk factors is a history of previous GTD. Women who have had a molar pregnancy or other forms of GTD are at a higher risk of recurrence in future pregnancies. Additionally, women who have experienced miscarriages or stillbirths may have a slightly increased risk.

A history of infertility or difficulty conceiving is another important medical risk factor. Women who have undergone fertility treatments, such as in vitro fertilization (IVF), may have a slightly higher risk of developing GTD, though the overall risk remains low. Discussing your medical history with your healthcare provider is essential for assessing individual risk factors.

Genetic and Age-Related Risk Factors

Genetic factors can also contribute to the development of gestational trophoblastic disease. In rare cases, specific genetic mutations may increase the likelihood of abnormal cell growth in the uterus. Additionally, women of certain ethnic backgrounds, particularly those of Asian descent, may have a higher risk of developing GTD.

Age is another critical factor. Women under 20 and over 35 are at a higher risk of developing GTD, with the risk increasing significantly for women over 40. Women in these age groups should be aware of the symptoms and risk factors associated with GTD and seek medical attention if they experience unusual symptoms during pregnancy.

Clinical Manifestations of Gestational Trophoblastic Disease

Nausea and Vomiting

Nausea and vomiting affect approximately 50-75% of patients with gestational trophoblastic disease (GTD). These symptoms are often more severe than in a normal pregnancy due to abnormally high levels of human chorionic gonadotropin (hCG) produced by the trophoblastic tissue. hCG stimulates the ovaries to produce progesterone, which maintains pregnancy. However, in GTD, excessive hCG production can overstimulate the body, leading to intense nausea and vomiting, sometimes referred to as hyperemesis gravidarum. This can occur early in the disease and may be one of the first warning signs.

Abdominal Pain

Abdominal pain is reported in about 20-30% of GTD patients. This pain is often due to the rapid growth of abnormal trophoblastic tissue, causing the uterus to enlarge more quickly than in a typical pregnancy. The stretching of uterine muscles and surrounding tissues can lead to discomfort or pain. In some cases, the pain may be sharp or cramp-like, especially if there is bleeding or if the abnormal tissue is pressing on nearby organs. Abdominal pain may also signal complications, such as the invasion of trophoblastic tissue into the uterine wall.

Vaginal Bleeding

Vaginal bleeding is one of the most common symptoms of GTD, occurring in about 80-90% of cases. The bleeding is often irregular and can range from light spotting to heavy bleeding. It is caused by the abnormal growth of trophoblastic tissue, which can invade the uterine lining and disrupt blood vessels. This bleeding may occur early in the disease and is often mistaken for a miscarriage or other pregnancy-related complication. In some cases, the bleeding may be accompanied by the passage of grape-like cysts, characteristic of a molar pregnancy, a type of GTD.

Enlarged Uterus

An enlarged uterus is seen in about 50% of GTD patients. The uterus may grow larger than expected for the gestational age due to the rapid proliferation of trophoblastic tissue. This abnormal growth can cause the uterus to expand more quickly than in a normal pregnancy, leading to a noticeable increase in abdominal size. In some cases, the uterus may be so large that it causes discomfort or pressure on surrounding organs. An enlarged uterus is often detected during a pelvic exam or ultrasound and can be an important clue in diagnosing GTD.

High hCG Levels

Elevated hCG levels are a hallmark of GTD, often much higher than in a normal pregnancy. In GTD, hCG levels can reach 100,000 IU/L or higher, compared to the typical range of 25,000-50,000 IU/L in a healthy pregnancy. These high levels result from the overproduction of hCG by abnormal trophoblastic tissue. Elevated hCG levels can lead to other GTD symptoms, including nausea, vomiting, and hyperthyroidism. Monitoring hCG levels is crucial for diagnosing and tracking the disease’s progression.

Preeclampsia

Preeclampsia, characterized by high blood pressure and protein in the urine, occurs in about 25% of GTD patients, particularly those with a complete molar pregnancy. While preeclampsia typically develops later in pregnancy, in GTD, it can occur as early as the first trimester. The exact cause is unclear, but it is thought to be related to abnormal placental tissue and high hCG levels. Untreated preeclampsia can lead to serious complications, such as seizures, kidney damage, and liver problems.

Hyperthyroidism

Hyperthyroidism affects about 10-15% of GTD patients. This condition is caused by high hCG levels, which can stimulate the thyroid gland to produce excess thyroid hormones. Symptoms include rapid heartbeat, weight loss, anxiety, and sweating. In some cases, hyperthyroidism can be severe and require treatment. Monitoring thyroid function in GTD patients is essential, as untreated hyperthyroidism can lead to serious complications.

Shortness of Breath

Shortness of breath is a less common symptom of GTD, occurring in about 5-10% of patients. It usually indicates more advanced disease, particularly if the trophoblastic tissue has spread to the lungs (metastatic GTD). The abnormal tissue can cause fluid buildup in the lungs or blockages in the airways, leading to difficulty breathing. If shortness of breath occurs, seek medical attention immediately, as it may indicate a serious complication.

Pelvic Pressure

Pelvic pressure is reported in about 20-30% of GTD patients. This sensation of heaviness or fullness in the pelvic area is often due to an enlarged uterus or the presence of abnormal tissue in the pelvic region. The pressure may be constant or intermittent and can be uncomfortable, especially when sitting or standing for long periods. In some cases, pelvic pressure may be accompanied by pain or discomfort in the lower back or abdomen.

Diagnostic Evaluation of Gestational Trophoblastic Disease

Diagnosing gestational trophoblastic disease (GTD) involves a combination of clinical evaluation, imaging studies, and laboratory tests. The first step is often a pelvic examination and a review of the patient’s symptoms and medical history. However, a definitive diagnosis requires further testing, including ultrasound, serum hCG levels, and sometimes advanced imaging techniques like MRI or CT scans. In some cases, a biopsy and histopathological examination of the tissue may be necessary to confirm the diagnosis. Genetic testing may also help differentiate between different types of GTD. Early and accurate diagnosis is crucial for effective treatment and monitoring.

Ultrasound

Test Information

An ultrasound is a non-invasive imaging test that uses sound waves to create images of the uterus and surrounding structures. During the test, a technician applies a gel to the abdomen and uses a handheld device called a transducer to capture images. In some cases, a transvaginal ultrasound may be performed, where the transducer is inserted into the vagina for a closer view of the uterus. Ultrasound is essential in diagnosing GTD because it can reveal abnormal tissue, such as a molar pregnancy, and assess the size and shape of the uterus. It can also help detect complications, such as the spread of trophoblastic tissue to other organs.

Results that Indicate GTD

In GTD cases, an ultrasound may show a characteristic “snowstorm” or “cluster of grapes” appearance, caused by the abnormal growth of trophoblastic tissue. This appearance is most commonly seen in complete molar pregnancies. In partial molar pregnancies, the ultrasound may reveal a fetus with abnormalities, along with cystic changes in the placenta. If the ultrasound shows these findings, further testing, such as serum hCG levels, will be ordered to confirm the diagnosis. If the ultrasound is negative but symptoms persist, additional tests, such as MRI or biopsy, may be needed to rule out other conditions.

Serum hCG Levels

Test Information

Serum hCG testing measures the level of human chorionic gonadotropin (hCG) in the blood. This hormone is produced by the placenta during pregnancy, but in GTD, hCG levels are often abnormally high due to the overgrowth of trophoblastic tissue. The test is performed by drawing a blood sample, which is then analyzed in a laboratory. Monitoring hCG levels is crucial for diagnosing GTD, as well as tracking the progression of the disease and the effectiveness of treatment. Serial hCG measurements are often taken over time to monitor changes in hormone levels.

Results that Indicate GTD

In GTD, hCG levels are typically much higher than in a normal pregnancy. For example, levels may exceed 100,000 IU/L, compared to the normal range of 25,000-50,000 IU/L in a healthy pregnancy. Persistently high or rising hCG levels after a pregnancy or miscarriage can also indicate the presence of GTD. If hCG levels are elevated, further testing, such as ultrasound or biopsy, will be performed to confirm the diagnosis. If hCG levels are normal but symptoms persist, other conditions, such as ectopic pregnancy or miscarriage, may need to be considered.

MRI

Test Information

Magnetic resonance imaging (MRI) is an advanced imaging technique that uses a magnetic field and radio waves to create detailed images of the body’s internal structures. Unlike X-rays or CT scans, MRI does not use ionizing radiation, making it a safer option for pregnant women. During the test, the patient lies on a table that slides into a large, tube-shaped machine. MRI is particularly useful in GTD for assessing the extent of the disease and determining whether the abnormal tissue has spread to other organs, such as the brain, liver, or lungs.

Results that Indicate GTD

In GTD, MRI may reveal the presence of abnormal tissue in the uterus or other organs. For example, if the disease has spread to the lungs or brain, MRI can help identify metastatic lesions. MRI is also useful for evaluating the depth of invasion of the trophoblastic tissue into the uterine wall, which can help guide treatment decisions. If the MRI is negative but symptoms persist, other imaging tests, such as a CT scan or chest X-ray, may be needed to rule out metastasis or other conditions.

CT Scan

Test Information

A computed tomography (CT) scan is an imaging test that uses X-rays and computer technology to create cross-sectional images of the body. The test is performed by having the patient lie on a table that slides into a large, doughnut-shaped machine. CT scans are particularly useful in GTD for detecting the spread of the disease to other organs, such as the lungs, liver, or brain. In some cases, a contrast dye may be injected into a vein to enhance the images and provide more detailed information about the extent of the disease.

Results that Indicate GTD

In GTD, a CT scan may show the presence of abnormal tissue in the uterus or other organs. For example, if the disease has spread to the lungs, the CT scan may reveal nodules or masses in the lung tissue. CT scans are also useful for detecting metastasis to the liver or brain. If the CT scan is negative but symptoms persist, further testing, such as a biopsy or genetic testing, may be needed to confirm the diagnosis.

What if all Tests are Negative but Symptoms Persist?

If all diagnostic tests come back negative but symptoms of GTD persist, it is important to continue working with your healthcare provider to explore other possible causes of your symptoms. In some cases, additional testing, such as a repeat ultrasound or MRI, may be needed to rule out other conditions, such as an ectopic pregnancy or miscarriage. Your healthcare provider may also recommend close monitoring of your symptoms and hCG levels over time to ensure that any changes are detected early. If necessary, a referral to a specialist, such as a gynecologic oncologist, may be made for further evaluation.

Treatment Options for Gestational Trophoblastic Disease

Medications for GTD Treatment

Methotrexate

Definition: Methotrexate is a chemotherapy drug that targets rapidly dividing cells, such as cancer cells, to stop their growth. It is commonly used to treat gestational trophoblastic disease (GTD) by halting the abnormal cell proliferation.

How and When It’s Used: Methotrexate is often the first-line treatment for low-risk GTD, particularly in cases of hydatidiform mole. It can be administered either by injection or orally, depending on the specific case. Treatment is typically given in cycles, with rest periods in between to allow the body to recover. It is most effective in early-stage disease with a low tumor burden.

Expected Outcomes: Patients can expect a reduction in tumor size and a decrease in hCG levels, which are markers of the disease. Most individuals respond well within weeks to months of starting treatment.

Actinomycin D

Definition: Actinomycin D is a chemotherapy agent that inhibits DNA synthesis in cancer cells, preventing them from multiplying.

How and When It’s Used: Actinomycin D is often used as a second-line treatment for GTD, especially if methotrexate is ineffective or if resistance develops. It is administered intravenously and is typically used in more advanced or persistent cases.

Expected Outcomes: Patients can expect tumor shrinkage and lower hCG levels, with improvement often seen after a few treatment cycles.

Etoposide

Definition: Etoposide is a chemotherapy drug that inhibits topoisomerase, an enzyme necessary for cancer cell division and growth.

How and When It’s Used: Etoposide is usually reserved for advanced or high-risk GTD cases. It is often combined with other chemotherapy drugs to enhance its effectiveness and is administered intravenously as part of a multi-drug regimen.

Expected Outcomes: Etoposide can lead to significant tumor shrinkage and a decrease in hCG levels, though full results may take several weeks.

Cyclophosphamide

Definition: Cyclophosphamide is a chemotherapy drug that damages the DNA of cancer cells, preventing them from multiplying.

How and When It’s Used: Cyclophosphamide is generally used in more aggressive or resistant forms of GTD. It is often combined with other chemotherapy agents in high-risk cases and is administered intravenously as part of a multi-drug treatment plan.

Expected Outcomes: Cyclophosphamide can reduce tumor size and hCG levels, though several treatment cycles may be needed for significant improvement.

Dactinomycin

Definition: Dactinomycin is a chemotherapy drug that binds to DNA, preventing cancer cells from replicating.

How and When It’s Used: Dactinomycin is often used in combination with other chemotherapy drugs for high-risk or recurrent GTD. It is administered intravenously and is typically used when first-line treatments like methotrexate are ineffective.

Expected Outcomes: Dactinomycin can lead to tumor shrinkage and lower hCG levels, with improvement usually seen within a few treatment cycles.

Vincristine

Definition: Vincristine is a chemotherapy drug that inhibits the formation of microtubules, which are necessary for cancer cell division.

How and When It’s Used: Vincristine is typically used in combination with other chemotherapy drugs for high-risk or resistant GTD cases. It is administered intravenously as part of a multi-drug regimen.

Expected Outcomes: Vincristine can reduce tumor size and hCG levels, though full results may take several weeks.

Carboplatin

Definition: Carboplatin is a chemotherapy drug that damages the DNA of cancer cells, preventing them from growing and dividing.

How and When It’s Used: Carboplatin is often used in combination with other chemotherapy drugs for high-risk or recurrent GTD. It is administered intravenously and is typically reserved for more advanced cases.

Expected Outcomes: Carboplatin can lead to significant tumor shrinkage and lower hCG levels, though several treatment cycles may be needed for full results.

Ifosfamide

Definition: Ifosfamide is a chemotherapy drug that interferes with the DNA of cancer cells, preventing them from multiplying.

How and When It’s Used: Ifosfamide is typically used in combination with other chemotherapy drugs for high-risk or resistant GTD cases. It is administered intravenously as part of a multi-drug regimen.

Expected Outcomes: Ifosfamide can reduce tumor size and hCG levels, though full results may take several weeks.

Gemcitabine

Definition: Gemcitabine is a chemotherapy drug that inhibits DNA synthesis in cancer cells, preventing them from dividing and growing.

How and When It’s Used: Gemcitabine is typically used in combination with other chemotherapy drugs for high-risk or recurrent GTD. It is administered intravenously and is often reserved for more advanced cases.

Expected Outcomes: Gemcitabine can lead to significant tumor shrinkage and lower hCG levels, though several treatment cycles may be needed for full results.

Improving Gestational Trophoblastic Disease Recovery and Seeking Medical Help

While medical treatments are essential for managing gestational trophoblastic disease, there are steps you can take at home to support your recovery and enhance your overall well-being. These include:

1. Rest and Recovery: Ensure you get plenty of rest to allow your body to heal from treatments.
2. Healthy Diet: A balanced diet rich in fruits, vegetables, and lean proteins can support your immune system and overall health.
3. Hydration: Staying well-hydrated is crucial, especially during chemotherapy, which can cause dehydration.
4. Stress Management: Practice relaxation techniques like meditation or deep breathing to manage stress, which can affect recovery.
5. Regular Monitoring: Keep up with follow-up appointments and hCG level checks to ensure the disease is under control.

If you experience new or worsening symptoms, such as increased bleeding, severe pain, or signs of infection, seek medical help immediately. Telemedicine offers a convenient way to consult with your healthcare provider from home, ensuring timely care without the need for in-person visits.

Living with Gestational Trophoblastic Disease: Tips for Better Quality of Life

Living with gestational trophoblastic disease can be challenging, but there are ways to improve your quality of life during treatment and recovery:

1. Stay Informed: Understanding your condition and treatment options can help you feel more in control of your health.
2. Build a Support System: Lean on family, friends, or support groups to help you cope emotionally and physically.
3. Maintain a Positive Outlook: Focus on the progress you’re making and celebrate small victories along the way.
4. Stay Active: Gentle exercise, such as walking or yoga, can improve your mood and energy levels.
5. Communicate with Your Healthcare Team: Keep an open line of communication with your healthcare provider to address any concerns or side effects.

Conclusion

Gestational trophoblastic disease is a rare but treatable condition affecting tissues formed during pregnancy. Early diagnosis and treatment are crucial for the best outcomes. With a range of effective treatments, including chemotherapy and supportive care, most patients can expect a full recovery. If you suspect symptoms of GTD or have been diagnosed, seek medical care promptly.

Our telemedicine practice offers a convenient way to consult with healthcare providers from home. Early intervention can significantly impact your treatment journey, so don’t hesitate to reach out for support.

James Kingsley

Learn More